Teva Pharmaceutical (NYSE:TEVA) shares gained more than 9% on Wednesday after the company reported better-than-expected first-quarter earnings and raised its full-year profit forecast, signaling continued momentum across its branded and generic drug portfolio.
The company posted adjusted earnings of $0.52 per share, topping the $0.48 analyst estimate. Revenue rose 5% year-over-year in local currency to $3.9 billion, just shy of the $3.98 billion consensus.
Teva’s performance was powered by strong gains in its core products. AUSTEDO sales surged 39% to $411 million, while AJOVY revenue increased 26% to $139 million. The generics division also posted growth across all geographic regions, reflecting broader market strength and operational improvements.
CEO Richard Francis highlighted the company’s ongoing progress, marking its ninth consecutive quarter of revenue growth. He emphasized Teva’s focus on accelerating its innovative pipeline, expanding its generics leadership, and driving operational efficiency.
Reflecting the solid start to the year, Teva raised its 2025 adjusted EPS guidance to $2.45–$2.65 from $2.35–$2.65, while narrowing its revenue outlook to $16.8–$17.2 billion from the prior $17.0–$17.4 billion range.